INNOVACAP Innova Captab Q2 FY26 results (Jul–Sep 2025) and concall
Innova Captab delivered a robust Q2 and H1 FY26, with consolidated revenue growing 19.5% YoY despite declining API prices. Both CDMO and Branded Generics segments showed strong growth, driven by market expansion and product portfolio. The company maintained EBITDA margins around 15% and is optimistic about sustaining growth momentum, supported by a strong order book and operational efficiencies. The Jammu facility is ramping up, contributing to future growth, though the recent GST rate reduction will necessitate higher sales volumes to achieve full incentives.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 19.5%, net profit down 14.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 318 | 316 | 315 | 352 | 380 +19% |
| EBITDA | 50 | 47 | 48 | 52 | 52 +4% |
| Net profit | 35 | 34 | 30 | 31 | 30 −14% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
